BioSpace News Archive

SR Instruments, a leading manufacturer of purpose-built scales for hospitals, medical centers, and long-term care facilities, announced that its flagship product line, SR Scales, has expanded its number of touchless scales.

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced a strategic partnership between its Early Phase Clinical Unit (EPCU) in Berlin, Germany and Clinical Trial Center (CTC) North, a full-service CRO located at the University Medical Center Hamburg-Eppendorf (UKE). The strategic collaboration support

CVS Health Corporation announced that Neela Montgomery has been named Executive Vice President and President of CVS Pharmacy/Retail, effective November 30, 2020.

Partnership will use AI to match patients with the best treatments based on their biological profiles. Work in Florida will serve as a model for the rest of the USA

The growth of the global insulin biosimilars market largely hinges onto advancements in medical analysis and research.

The medical vending machines market may gain exponential growth across the assessment period of 2020-2030 on the back of the rising influence of automation in the healthcare sector and the preference of the populace for extensive reliability and efficiency.

The tip location devices market may gain prominent growth across the forecast period of 2020-2030 on the back of the growing demand for catheterization procedures and the diverse technological advancements over the years.

A rising need for expansion of healthcare access together with growth of the geriatric population unable to travel down to healthcare facilities is likely to play an important role in the development of the global remote patient monitoring market over the timeframe of analysis, from 2019 to 2029.

Novalis Biotech, an early stage venture capital investor in technologies to revolutionize healthcare, announced the successful first closing of its second fund, Novalis Biotech Acceleration, raising an initial €8 million.

Innovent Biologics, Inc. announced that SULINNO®, a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration of China for the treatment of polyarticular juvenile idiopathic arthritis, which is the fourth approved indication of SULINNO® in China.